Radionetics Oncology, Inc. is a clinical stage company focused on the discovery and development of novel radiopharmaceuticals for the treatment of a wide range of oncology indications and is poised to capitalize on the increasing demand for novel radiotherapeutics. Radionetics Oncology is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Global Investments and has entered into a strategic agreement with Eli Lilly. Radionetics is advancing a pipeline of first-in-class small molecule radioligands targeting G protein coupled receptors for the treatment of a broad range of cancers, including breast cancer, lung cancer, and other indications of high unmet need. The VP/ Senior VP of Clinical Development, is a critical leadership role working closely with the CMO on the design, execution, and interpretation of clinical trials for our novel radiopharmaceutical pipeline in oncology. This individual will serve as a medical and scientific lead for assigned programs, providing strategic and operational direction to advance our innovative therapies through first-in-human studies. The successful candidate will be a board-certified Medical Doctor (MD) with significant experience in oncology drug development, preferably with specific expertise in radioligand therapy (RLT) or nuclear medicine. The exact title (Medical Director, VP, SVP) will be determined based on the candidate's experience, scope of responsibility, and proven track record.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Executive
Education Level
Ph.D. or professional degree